Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.59 |
| ▸ | TDO2 | P48775 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 4/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886586 | 0.86 | NPSR1 (0.58) | IDO1TDO2CHEK1MAP2K4TTK | |
| SCHEMBL2883740 | 0.85 | NPSR1 (0.46) | IDO1TDO2CHEK1TTKHPGD | |
| SCHEMBL2886777 | 0.84 | ATM (0.55) | IDO1TDO2CHEK1MAP2K4TTK | |
| SCHEMBL2880879 | 0.79 | ATM (0.45) | CHEK1MAP2K4ATMNPSR1DYRK1A | |
| SCHEMBL7298569 | 0.79 | ATM (0.69) | IDO1LRRK2PIM1PIM2PIM3 | |
| SCHEMBL2886307 | 0.76 | LRRK2 (0.56) | LRRK2PIM1PIM2CHEK1HPGD | |
| SCHEMBL2887042 | 0.76 | DYRK1A (0.63) | HPGDCDK4CCND1DYRK1APARP1 | |
| SCHEMBL30725847 | 0.76 | IDO1 (1.00) | IDO1LRRK2TDO2PIM1CYP11B1 | |
| SCHEMBL12318034 | 0.76 | IDO1 (1.00) | IDO1LRRK2TDO2PIM1CYP11B1 | |
| SCHEMBL2891171 | 0.73 | ADORA2A (0.53) | TDO2CHEK1CDK4CCND1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035429-B1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON INC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2035429-B1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON INC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149557-A1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CDK5, CDK5R1, CDK7 | IDO1 1290/4885LRRK2 412/4885TDO2 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.